AnaptysBio - Home
About
Overview
Strategy
Senior Leadership
Board of Directors
Scientific Advisory Board
Contact
Technology
Therapeutic Antibodies
Somatic Hypermutation
SHM Platform
Key Advantages
Publications
Pipeline
Overview
Rosnilimab
ANB032
ANB033
Imsidolimab
Partnerships
Investors / News
Overview
News
Events
Presentations
Goverance
Stock Information
Analyst Coverage
SEC Filings
Investor FAQs
Contact
Careers
Overview
Job Openings
Core Values
Total Rewards Program Highlights
AnaptysBio Culture
Contact
Toggle
Therapeutic Antibodies
for Severe Disease
January 13, 2023
AnaptysBio Announces Stock Repurchase Plan
AnaptysBio Announces Stock Repurchase Plan
January 5, 2023
AnaptysBio Announces Portfolio Update Across Best-in-Class Immune Cell Modulating Antibodies
AnaptysBio Announces Portfolio Update Across Best-in-Class Immune Cell Modulating Antibodies
December 2, 2022
AnaptysBio- and GSK-partnered immuno-oncology agent JEMPERLI (dostarlimab-gxly) meets primary endpoint in Phase 3 RUBY trial in primary advanced or recurrent endometrial cancer
AnaptysBio- and GSK-partnered immuno-oncology agent JEMPERLI (dostarlimab-gxly) meets primary endpoint in Phase 3 RUBY trial in primary advanced or recurrent endometrial cancer
About
Technology
Pipeline
Investors
Careers
